GH SEC Filings

Guardant Health, Inc. reported strong revenue growth of 44% year-over-year for the second quarter of 2026, reaching $335.0 million, and 46% for the first six months, totaling $636.6 million. This growth was primarily driven by a significant increase in test volumes across its oncology and, notably, its screening segment, with Shield screening test volume more than tripling. Despite this robust top-line performance, the company continued to incur substantial net losses, reporting $120.1 million for the quarter and $232.2 million for the first six months. These losses are a result of continued heavy investment in research and development, and a significant increase in sales and marketing expenses, up 59% and 60% for the respective periods, to support commercial expansion and product adoption. The company's balance sheet shows a healthy cash position of $1.2 billion as of June 30, 2026, providing ample liquidity for continued operations and investment. However, investors should note the ongoing legal proceedings, particularly the intellectual property dispute with TwinStrand Biosciences, which resulted in a significant jury verdict against Guardant Health, with a potential loss estimated between $0 and $250 million. While the company is contesting this verdict and has favorable developments in USPTO reviews of the patents, this remains a material contingent liability.

Guardant Health, Inc. (GH) has filed an 8-K report on July 30, 2026, to announce its financial results for the fiscal quarter ended June 30, 2026. The primary purpose of this filing is to furnish the accompanying press release, which contains the detailed financial and operational performance for the period. Investors should refer to Exhibit 99.1, the press release itself, for the specific figures and management commentary regarding revenue, profitability, and key performance indicators. While the 8-K itself provides a formal notification of the release, the substantive information is contained within the press release. Investors are advised to carefully review this press release for insights into the company's top-line growth, cost management, and any forward-looking guidance provided by Guardant Health. This information is crucial for assessing the company's current financial health and future prospects within the competitive landscape of precision oncology.

Guardant Health, Inc. (GH) held its Annual Meeting of Stockholders on June 17, 2026, with the results detailed in this 8-K filing. Key outcomes include the election of all director nominees and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The company also sought advisory votes on executive compensation and the frequency of future advisory votes on executive compensation. While director elections and auditor ratification were strongly supported by shareholders, the advisory vote on executive compensation ("Say-on-Pay") did not receive majority approval. This indicates a potential disconnect between management's compensation practices and shareholder sentiment. Furthermore, shareholders voted overwhelmingly in favor of an annual advisory vote on executive compensation, suggesting a desire for more frequent engagement on this matter.

Guardant Health, Inc. reported a significant increase in revenue for the first quarter of 2026, reaching $301.7 million, a 48% jump from the prior year's $203.5 million. This growth was primarily driven by a substantial increase in test volumes across its oncology and screening segments, with the Shield screening test showing remarkable 633% revenue growth. Despite strong top-line performance, the company continued to experience operating losses, with a net loss of $112.1 million for the quarter, compared to $95.2 million in the same period last year. This widening net loss reflects increased operating expenses, particularly in sales and marketing, which grew by 62% to support commercial expansion and marketing initiatives. The company maintains a solid liquidity position with approximately $1.2 billion in cash, cash equivalents, and marketable securities as of March 31, 2026, which it believes is sufficient to fund operations for over 12 months.

Guardant Health, Inc. (GH) filed an 8-K on May 7, 2026, to report its financial results for the fiscal quarter ended March 31, 2026. The press release, furnished as Exhibit 99.1, provides the key financial and operational data investors need to assess the company's performance. Investors should review this press release for details on revenue, profitability, cash flow, and any forward-looking guidance. While specific financial figures are not detailed within the 8-K itself, the filing serves as the official channel for disseminating this crucial information. The incorporation by reference of the press release means that all information contained within it is considered part of the company's public disclosures. Investors are advised to access Exhibit 99.1 directly for a comprehensive understanding of Guardant Health's first-quarter 2026 performance and its implications for future growth and market position.

Guardant Health, Inc. (GH) announced a significant change in its executive leadership with the resignation of its Chief Medical Officer, Craig Eagle, M.D., effective May 8, 2026. This departure marks the end of Dr. Eagle's tenure in a critical role overseeing the company's medical strategy and clinical development, particularly relevant given Guardant Health's focus on cancer diagnostics and precision medicine. Investors will be keen to understand the implications of this change on the company's ongoing research, clinical trial progress, and its overall medical vision moving forward. The company has not yet announced a successor for Dr. Eagle. The absence of immediate plans for a replacement could suggest a period of transition or a strategic review of the CMO role. Investors should closely monitor future filings and communications from Guardant Health for updates on leadership appointments and any potential shifts in the company's medical and scientific direction.

Guardant Health, Inc. (GH) has filed an 8-K on February 19, 2026, to announce its financial results for the fiscal quarter and year ended December 31, 2025. The key details of these results are contained within a press release furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for specific performance metrics, revenue figures, profitability, and any forward-looking guidance provided by the company. While the 8-K itself is a procedural filing, the accompanying press release is the critical document for understanding Guardant Health's recent financial performance and its outlook. Investors will be looking for information regarding the growth in their diagnostic testing volume, reimbursement trends, and progress in commercializing their liquid biopsy solutions for cancer detection and monitoring. Any updates on clinical trial progress or regulatory approvals for their products would also be highly relevant.

Guardant Health, Inc. (GH) has filed its 10-K for the fiscal year ending December 31, 2025. The company reported total revenue of $982.0 million, a significant increase of 33% from the prior year, driven by strong growth in both its Oncology and Biopharma & Data segments. Despite this revenue growth, Guardant Health continued to incur substantial net losses, reporting a net loss of $416.3 million for the year, which is an improvement from the $436.4 million net loss in 2024. The company's expansion of its sales and marketing efforts, particularly for its Shield blood test for colorectal cancer screening, contributed to increased operating expenses, with sales and marketing expenses rising 36% year-over-year. Guardant Health remains focused on its strategic objectives of expanding clinical utility, increasing reimbursement, and strengthening customer relationships across its product portfolio, which spans therapy selection, minimal residual disease detection, and early cancer screening. Financially, the company ended the year with a strong cash position of approximately $1.3 billion in cash, cash equivalents, and marketable debt securities, providing ample runway. Key developments include the FDA approval and commercial availability of the Shield blood test for colorectal cancer screening, and continued investment in R&D to expand its technology platform. However, the company continues to face significant risks related to its profitability, ongoing losses, reimbursement uncertainties from payers, competitive pressures, and potential regulatory changes.

Guardant Health, Inc. (GH) has filed an 8-K report on January 12, 2026, disclosing preliminary unaudited financial information for the fourth quarter and full year ended December 31, 2025. This information is detailed in a press release furnished as Exhibit 99.1 to the filing. While specific financial metrics are not detailed in the 8-K itself, investors should refer to the press release for details on revenue, earnings, and other key performance indicators relevant to the period. In addition to the financial results, the Company also announced that a presentation for the 2026 J.P. Morgan Healthcare Conference, scheduled for January 12, 2026, will be made available on their investor website. This presentation is likely to offer further insights into the Company's strategic priorities, market outlook, and potentially updated guidance. Investors are advised to review both the press release and the conference presentation for a comprehensive understanding of Guardant Health's current financial standing and future prospects.

Guardant Health, Inc. (GH) has announced the successful completion of two significant financing transactions: a public offering of common stock and a private offering of convertible senior notes, both of which closed on November 7, 2025. The common stock offering raised approximately $327.2 million in net proceeds after deducting underwriting discounts and expenses, involving the sale of 3,833,332 shares at $90.00 per share. Concurrently, the company raised approximately $390.0 million in net proceeds from the sale of $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2033. These combined financings, totaling over $717 million in net proceeds, are intended for general corporate purposes. A key stated use of these funds, depending on market conditions, is the potential repurchase of a portion of the Company's existing 0% convertible senior notes due 2027. The increased sizes of both offerings indicate strong investor demand and provide Guardant Health with substantial capital to support its ongoing operations and strategic initiatives.

Guardant Health, Inc. (GH) filed an 8-K on October 29, 2025, primarily to report its financial results for the fiscal quarter ended September 30, 2025. The key details of these results are available in the press release furnished as Exhibit 99.1. Investors should review this press release for specific revenue figures, profitability metrics, and any forward-looking guidance provided by the company. While this 8-K itself doesn't contain detailed financial tables, it serves as the official notification that the company has disseminated its quarterly performance update.

Guardant Health, Inc. reported a significant increase in revenue for the third quarter and first nine months of 2025, driven by strong performance in its Oncology and Biopharma segments. Total revenue grew by 39% year-over-year for the quarter to $265.2 million and by 30% for the nine-month period to $700.8 million. Despite revenue growth, the company continues to incur net losses, reporting a net loss of $92.7 million for the third quarter and $287.8 million for the nine months ended September 30, 2025. The company's significant investments in research and development, coupled with increased sales and marketing expenses to support product launches like Shield, contribute to these ongoing losses. However, the company maintains a healthy liquidity position with $689.5 million in cash, cash equivalents, and restricted cash as of September 30, 2025, suggesting sufficient runway for operations.

Guardant Health, Inc. (GH) announced an upcoming Investor Day scheduled for September 24, 2025. This event will provide an opportunity for investors to hear directly from co-CEOs Helmy Eltoukhy and AmirAli Talasaz, along with other members of the executive management team. The presentations are expected to focus on the company's operational performance, strategic priorities, and updated financial outlook. This Investor Day presents a crucial opportunity for stakeholders to gain deeper insights into Guardant Health's current business trajectory and future plans. Investors should pay close attention to any new strategic initiatives, market expansion updates, and revisions to financial projections that may be shared during the event, as these could significantly impact the company's valuation and stock performance.

Guardant Health, Inc. (GH) has announced a significant addition to its Board of Directors with the appointment of Alex M. Azar II, former U.S. Secretary of Health and Human Services. This move, effective September 12, 2025, increases the board size to 11 members and brings a wealth of experience in healthcare policy and leadership to the company. Mr. Azar's appointment is effective until the 2027 Annual Meeting of Stockholders and includes a role on the nominating and corporate governance committee. His compensation includes standard director awards of stock options and restricted stock units valued at $362,500, with a staggered vesting schedule over four years. This strategic appointment underscores Guardant Health's commitment to strengthening its governance and leveraging high-level expertise as it continues to advance its position in the liquid biopsy and precision oncology market.

Guardant Health, Inc. reported a significant increase in revenue for the second quarter and first half of 2025, driven by strong performance in its Oncology and Biopharma and Data segments. Total revenue for the three months ended June 30, 2025, was $232.1 million, up 31% year-over-year, and for the six months ended June 30, 2025, revenue reached $435.6 million, a 26% increase. The company also saw initial revenue from its newly launched Shield screening test. Despite revenue growth, Guardant Health continued to incur net losses, with a loss of $99.9 million for the quarter and $195.1 million for the first half of the year. The company's cash position remains robust with $735.5 million in cash, cash equivalents, and restricted cash as of June 30, 2025, providing ample liquidity for over 12 months. Key developments include the expanding commercial reach of the Shield test, which received National Comprehensive Cancer Network guideline inclusion and met Medicare coverage requirements, alongside continued investment in research and development. The company also successfully managed its debt structure by completing a note exchange transaction in February 2025, which retired a portion of its 2027 notes and resulted in a gain on extinguishment. Management anticipates continued investment in sales and marketing to drive adoption and expansion, particularly with the Shield product line and international growth initiatives.

Guardant Health, Inc. (GH) filed an 8-K on July 30, 2025, primarily to furnish a press release detailing its financial results for the fiscal quarter ended June 30, 2025. While the filing itself is brief, the incorporated press release (Exhibit 99.1) is the critical document for investors seeking insights into the company's recent performance. Investors should carefully review this press release for key financial metrics, operational updates, and forward-looking statements. This report serves as an important communication channel for Guardant Health to update the market on its progress. Investors are advised to look beyond the 8-K's formal structure and delve into the press release's content, which will contain the detailed financial performance, revenue figures, earnings per share, and any strategic developments or guidance for future periods. The information furnished herein is not deemed "filed" under Section 18 of the Exchange Act, meaning it does not carry the same legal implications as a formally filed document, but it remains crucial for understanding the company's financial health and trajectory.

Guardant Health, Inc. (GH) held its annual meeting of stockholders on June 18, 2025. The primary outcomes reported in this 8-K filing pertain to the election of directors, ratification of the independent auditor, and advisory approval of executive compensation. All director nominees presented in the proxy statement were elected, indicating strong shareholder confidence in the current board's composition and strategy. Additionally, shareholders overwhelmingly ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, a standard but important procedural approval for financial oversight. Furthermore, a non-binding advisory vote on the compensation of the company's named executive officers received majority approval. While the overall outcomes reflect shareholder support, investors should note the breakdown of votes for director nominee Musa Tariq, which showed a higher percentage of 'votes withheld' compared to other nominees. This is a point for potential further scrutiny or understanding of specific shareholder concerns. The strong ratification of the auditor and executive compensation proposals generally signal a stable governance environment.

Guardant Health, Inc. reported a notable increase in revenue for the first quarter of 2025, up 21% year-over-year to $203.5 million. This growth was primarily driven by strong performance in its Oncology and Biopharma and data segments, reflecting increased test volumes and improved reimbursement for key tests like Guardant360 CDx and Guardant Reveal. The company also saw the initial revenue contribution from its Shield screening test, a positive development for its early cancer detection strategy. Despite the revenue growth, the company continued to incur significant operating losses, with a net loss of $95.2 million for the quarter. This was partly due to increased investments in research and development and a substantial rise in sales and marketing expenses, particularly related to expanding its commercial team and supporting new product launches like Shield. The company's cash position remains strong at over $800 million, providing runway for continued investment. Investors will be closely watching the company's progress in commercializing its screening tests and managing its expenses to achieve profitability.

Guardant Health, Inc. (GH) has filed an 8-K report on April 30, 2025, to announce its financial results for the fiscal quarter ending March 31, 2025. The primary focus of this filing is the accompanying press release, which contains the detailed financial performance for the period. Investors should refer to this press release, furnished as Exhibit 99.1, for specific figures regarding revenue, profitability, and operational metrics. While the 8-K itself provides minimal detail, it serves as the official channel for disseminating these crucial quarterly results. The information within this 8-K, particularly the furnished press release, is critical for assessing Guardant Health's current business trajectory and future prospects. Investors will be looking for updates on key performance indicators relevant to the precision oncology market, such as test volumes, reimbursement status, and any strategic developments or guidance provided by the company. It is important to note that the information furnished under Item 2.02 is not considered "filed" for certain regulatory purposes, but its content remains highly relevant for investment decisions.

Guardant Health, Inc. has filed a Form 8-K to report on a material definitive agreement, specifically the third amendment to its existing lease for its Redwood City, California facilities. This amendment extends the lease term for various buildings within the facility to either December 31, 2030, or December 31, 2031. This extension comes with a commitment of approximately $50 million over the extended period, with base rent set to increase by 3% annually starting in 2026.

Guardant Health, Inc. (GH) has filed a Form 8-K on February 20, 2025, to announce its financial results for the fiscal quarter and full year ended December 31, 2024. The full details of these results are provided in a press release furnished as Exhibit 99.1 to the filing. This report serves as the primary channel for investors to access the company's latest financial performance data and operational updates for the fourth quarter and the entirety of 2024. Investors should review the furnished press release for critical information regarding revenue, profitability, key performance indicators, and any forward-looking guidance the company may have provided. As this filing primarily incorporates information by reference to the press release, direct engagement with Exhibit 99.1 is essential for a comprehensive understanding of Guardant Health's financial condition and operational results as of the end of 2024. The company has also included the cover page interactive data file as required.

Guardant Health, Inc. (GH) presented its 2024 Annual Report on Form 10-K, highlighting significant revenue growth driven by its precision oncology testing business, which increased by 34% year-over-year to $687.9 million. This growth was fueled by a 34% rise in clinical testing revenue, attributed to increased sample volumes and improved reimbursement rates, particularly from Medicare for its Guardant360 LDT test. Biopharmaceutical revenue also saw a 31% increase. Despite top-line growth, the company continues to incur substantial net losses, with the 2024 net loss at $436.4 million, a slight improvement from $479.4 million in 2023. The company ended the year with a strong liquidity position, holding $944.2 million in cash, cash equivalents, restricted cash, and marketable debt securities, providing ample runway for continued investment in research and development, clinical studies, and commercial expansion. The company achieved a major milestone with the FDA approval and subsequent commercial launch of its Shield blood test for colorectal cancer screening in August 2024, making it the first FDA-approved blood test for primary colorectal cancer screening that also meets Medicare coverage requirements. This positions Guardant Health to address the critical early cancer detection market. Looking ahead, Guardant Health remains focused on expanding clinical utility, securing broader payer coverage and reimbursement, and growing its global commercial footprint. However, investors should remain aware of the significant risks outlined, including the ongoing unprofitability, dependence on reimbursement decisions, competitive pressures, and potential regulatory changes, particularly concerning Laboratory Developed Tests (LDTs).

Guardant Health, Inc. (GH) announced a significant debt restructuring through privately negotiated exchange agreements, resulting in the issuance of $600 million aggregate principal amount of 1.25% Convertible Senior Notes due 2031 (New Notes). These New Notes were exchanged for approximately $659.3 million principal amount of its outstanding 0% Convertible Senior Notes due 2027. This transaction effectively reduced the principal amount of outstanding convertible debt by approximately $59.3 million while extending the maturity profile of a portion of its debt to 2031 and introducing a modest interest cost. Investors should note that the company has strategically extended its debt maturity and reduced its near-term debt principal. The New Notes carry a 1.25% annual interest rate and are convertible into Guardant Health common stock at an initial conversion price of approximately $62.22 per share, representing a conversion premium of about 35% to the stock price on February 6, 2025. This convertible note structure allows the company to potentially issue shares at a premium, which could mitigate dilution compared to a cash repayment, while also providing flexibility for future capital management.

Guardant Health, Inc. has executed privately negotiated exchange agreements to issue $600 million in aggregate principal amount of new 1.25% Convertible Senior Notes due 2031 (New Notes) in exchange for approximately $659.3 million of its outstanding 0% Convertible Senior Notes due 2027 (2027 Notes). This transaction effectively extends the maturity of a significant portion of its convertible debt and lowers the immediate cash interest expense. The exchange is expected to close on or about February 14, 2025. Following the transaction, approximately $490.7 million of the 2027 Notes will remain outstanding.

Guardant Health, Inc. (GH) filed an 8-K on January 13, 2025, primarily to disclose preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. The press release containing these results is furnished as Exhibit 99.1, which investors should review for specific financial performance metrics. The company also indicated that a presentation for the 2025 J.P. Morgan Healthcare Conference, scheduled for the same date, would be made available on their investor relations website.

Guardant Health, Inc. reported its third-quarter 2024 financial results, showcasing robust revenue growth driven by its precision oncology testing segment. Total revenue increased by 34% year-over-year to $191.5 million, with precision oncology testing revenue growing by 35% to $180.6 million. This growth was fueled by both increased test volumes from clinical customers and biopharmaceutical clients, along with improved reimbursement rates, particularly for the Guardant360 LDT test. Despite strong top-line performance, the company continues to operate at a net loss, reporting a loss of $107.8 million for the quarter. The company maintains a healthy liquidity position with approximately $1.0 billion in cash, cash equivalents, and marketable debt securities as of September 30, 2024, providing runway for continued investment in research and development and commercial expansion. A significant development during the quarter was the achievement of performance metrics for certain performance-based restricted stock units (PSUs), leading to a cumulative charge of $23.5 million in stock-based compensation expense. While R&D expenses saw a slight decrease year-over-year, sales and marketing expenses increased significantly due to commercial team build-out and marketing efforts for product launches, including the Shield test. The company also noted progress in its intellectual property disputes and continues to advance its product pipeline and international expansion efforts.

Guardant Health, Inc. (GH) has filed an 8-K report on November 6, 2024, primarily to furnish a press release detailing its financial results for the fiscal quarter ended September 30, 2024. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification mechanism for the company's quarterly performance announcement. Investors should refer to the furnished press release (Exhibit 99.1) for specific revenue, earnings, and operational metrics for the third quarter of 2024. This filing is a routine step for publicly traded companies to disseminate important financial information to the market in a timely manner. The key takeaway for investors is that the company has reported its Q3 2024 financial results. The 8-K's purpose is to make this information publicly available through the attached press release. Investors seeking a comprehensive understanding of Guardant Health's financial health, performance trends, and any forward-looking guidance should meticulously review the content of Exhibit 99.1. The filing itself, beyond referencing the press release, provides standard legal disclaimers regarding the 'furnished' nature of the information.

Guardant Health, Inc. (GH) has announced a significant update to its Board of Directors composition, effective October 21, 2024. The Board has been expanded to ten directors with the appointment of Roberto Mignone as a Class I director. Mr. Mignone brings extensive experience from the investment management sector, notably as the Founder and Managing Partner of Bridger Management LLC, a firm with a strong focus on the healthcare sector. His appointment is expected to enhance the Board's strategic oversight, particularly given his background in long-term equity strategies and deep research expertise in healthcare. In connection with his appointment, Mr. Mignone has also been appointed to the Board's audit committee, further reinforcing the company's governance structure. He will receive standard compensation for non-employee directors, including initial stock option and restricted stock unit awards valued at $362,500, with a vesting schedule tied to his continued service. The company has also entered into its standard indemnification agreement with Mr. Mignone. This move signals a potential strengthening of the Board's financial and strategic acumen, particularly relevant for a company operating in the rapidly evolving diagnostics and precision oncology market.

Guardant Health, Inc. (GH) has entered into an Open Market Sale Agreement with Jefferies LLC, establishing an at-the-market (ATM) offering program. This agreement allows the company to sell up to $400.0 million of its common stock from time to time, at its discretion, through Jefferies acting as the sales agent. The offering will be conducted under the company's existing shelf registration statement on Form S-3, filed on May 22, 2023, with a prospectus supplement filed concurrently with this report. This strategic move provides Guardant Health with flexibility to raise capital as needed to support its ongoing operations, growth initiatives, or strategic opportunities without needing to file a new registration statement immediately.

Guardant Health, Inc. reported a significant increase in total revenue for the second quarter and first half of 2024, driven primarily by its Precision Oncology Testing segment. Total revenue for the three months ended June 30, 2024, rose by 29% year-over-year to $177.2 million, and for the six months ended June 30, 2024, revenue grew by 30% to $345.7 million. Despite revenue growth, the company continued to incur substantial net losses, with a loss of $102.6 million for the quarter and $217.6 million for the first half of the year. This is a key area for investors to monitor, as is the company's substantial cash balance of $1.0 billion as of June 30, 2024, which provides a sufficient runway for more than 12 months. A significant development during the period was the FDA approval and subsequent commercial launch of the Shield blood test for colorectal cancer screening in August 2024, positioning Guardant Health as a leader in early cancer detection.

Guardant Health, Inc. (GH) filed an 8-K on August 7, 2024, to announce its financial results for the fiscal quarter ended June 30, 2024. The primary purpose of this filing is to furnish the press release containing these results, which is included as Exhibit 99.1. Investors should refer to this press release for detailed financial performance, operational updates, and forward-looking statements. The company explicitly notes that the information furnished in this 8-K, including the press release, is not deemed "filed" under Section 18 of the Exchange Act, meaning it does not carry the same legal liability as formally filed documents, but it is incorporated by reference into the company's filings under securities laws.

Guardant Health, Inc. (GH) announced a significant development on July 29, 2024, with the U.S. Food and Drug Administration (FDA) approving its Shield blood test. This approval is a major milestone, enabling the test to be used for screening colorectal cancer in adults aged 45 and older who are at average risk for the disease. This expands the addressable market for Guardant Health's liquid biopsy technology into a broader, average-risk population, moving beyond its previous focus on higher-risk individuals or specific clinical scenarios. The FDA approval for the Shield test represents a crucial step in Guardant Health's strategy to make its cancer screening solutions more accessible. Colorectal cancer is a leading cause of cancer death, and the availability of a non-invasive, blood-based screening option for average-risk individuals has the potential to significantly improve early detection rates and patient outcomes. This approval is expected to drive commercial adoption and revenue growth for the company.

Guardant Health, Inc. (GH) has announced a key change to its Board of Directors, appointing Dr. Manuel Hidalgo Medina as a Class II director. This appointment, effective July 17, 2024, expands the Board to nine members and brings significant expertise in anticancer drug development, particularly in gastrointestinal and pancreatic cancers, to the company's leadership. Dr. Hidalgo's extensive background includes leadership roles at prestigious institutions like Weill Cornell Medicine and Harvard Medical School, as well as experience with major pharmaceutical companies like Bristol-Myers Squibb. This strategic addition to the Board is expected to bolster Guardant Health's capabilities, especially in light of its focus on developing advanced cancer diagnostics and therapies. Dr. Hidalgo's compensation will include standard director awards of stock options and restricted stock units, valued at $362,500 collectively, vesting over a period of up to four years. The company also noted that there are no reportable arrangements or transactions involving Dr. Hidalgo that would require disclosure under Regulation S-K.

Guardant Health, Inc. (GH) reported the results of its 2024 Annual Meeting of Stockholders held on June 12, 2024. The meeting saw the election of all director nominees, indicating strong shareholder confidence in the current board's leadership and strategic direction. Furthermore, shareholders ratified the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, which is a standard procedural approval. However, a notable outcome was the advisory vote on executive compensation; the proposal to approve the compensation of named executive officers did not pass on a non-binding basis. This suggests some shareholder concerns or dissatisfaction regarding executive pay, which the company will need to address.

Guardant Health, Inc. (GH) filed an 8-K on May 31, 2024, detailing amendments to its Executive Severance Plan. These changes, effective May 24, 2024, primarily impact the severance packages for executive employees, particularly in scenarios involving termination without cause or for good reason, and in connection with a change in control. The amendments standardize severance benefits, with increased payouts and accelerated equity vesting for Co-CEOs Helmy Eltoukhy and AmirAli Talasaz, especially during a change in control event. The revised plan provides for enhanced severance benefits, including extended salary and COBRA payments, and accelerated vesting of equity awards. Notably, these enhanced benefits are more generous for Co-CEOs, with provisions for 18 to 24 months of salary and COBRA payments, and full or significantly accelerated vesting of their equity awards under specific termination conditions and change in control scenarios. These updates reflect a strategic review and aim to align executive compensation and retention with potential future corporate events.

Guardant Health, Inc. (GH) announced a significant development regarding its Shield blood test for colorectal cancer screening. On May 23, 2024, the company issued a press release detailing that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee has provided a strong recommendation for the approval of Shield. This recommendation specifically targets screening for colorectal cancer in adults aged 45 and older who are at average risk for the disease. The advisory committee's vote was overwhelmingly positive across key safety and efficacy measures. Panel members voted favorably regarding the test's safety (8-1), effectiveness (6-3), and the balance of benefits over risks (7-2). While this recommendation is a crucial step, it will be considered by the FDA as part of its ongoing premarket approval review for the Shield test. This positive advisory panel opinion signals strong potential for the Shield test to become a widely available screening option, which could significantly impact the landscape of colorectal cancer detection.

Guardant Health, Inc. reported a 31% increase in total revenue for the first quarter of 2024, reaching $168.5 million, driven primarily by a 38% surge in precision oncology testing revenue to $156.2 million. This growth was fueled by higher test volumes and improved reimbursement rates, particularly for their Guardant360 LDT and CDx tests. Despite the top-line growth, the company continued to operate at a significant net loss of $115.0 million, though this was an improvement from the $133.5 million loss in the prior year's quarter. The company's substantial cash reserves of $1.1 billion provide a strong liquidity position, enabling continued investment in research and development, including advancements in early cancer detection tests like Shield for colorectal and lung cancer.

Guardant Health, Inc. (GH) filed an 8-K on May 9, 2024, to announce its financial results for the fiscal quarter ended March 31, 2024. The key information is contained within the press release furnished as Exhibit 99.1. While specific financial figures are not detailed in the 8-K itself, investors should refer to the press release for comprehensive details on revenue, profitability, and other key performance indicators for the first quarter of 2024. This filing serves as the official notification of the company's performance. Investors should pay close attention to the press release for any updates on guidance, strategic initiatives, or significant operational developments that may impact the company's future outlook. The 8-K emphasizes that the information furnished is not considered "filed" under Section 18 of the Exchange Act, meaning it does not carry the same legal liabilities as filed reports, but it remains the primary source for the announced financial results.

Guardant Health, Inc. (GH) announced updates to the compensation arrangements for its Co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, effective January 1, 2024. The company has entered into new letter agreements that primarily adjust the incentive compensation structure, moving away from traditional salaries and cash bonuses towards equity awards. This move signals a continued focus on aligning executive compensation with long-term company performance and shareholder value creation. Key changes include maintaining a nominal base salary of $1 per year, with future salary adjustments to be determined by the Compensation Committee. Instead of salary and annual bonuses, each Co-CEO will receive annual grants of Restricted Stock Units (RSUs) and Performance-based RSUs (PSUs) valued at $800,000. Additionally, they will receive significant long-term awards of RSUs and PSUs valued at $5,000,000 each, tied to multi-year performance metrics. The cancellation of prior PSU awards is also noted. These adjustments underscore a strong emphasis on performance-driven incentives and long-term commitment from the leadership team.

Guardant Health, Inc. reported a total revenue of $563.9 million for the year ended December 31, 2023, a 25% increase year-over-year, driven primarily by a 31% rise in precision oncology testing revenue. Despite this top-line growth, the company continued to incur significant net losses, amounting to $479.4 million for the year. The company has a substantial cash and cash equivalents balance of $1.1 billion as of December 31, 2023, which it believes is sufficient to fund its operations for more than 12 months. The company is focused on expanding its product portfolio and market adoption, particularly with its Shield test for early cancer detection, for which a PMA was submitted to the FDA. However, significant risks remain, including the company's ongoing unprofitability, dependence on third-party payer coverage and reimbursement, and intense competition in the precision oncology market. A recent jury verdict in a patent infringement case resulted in an $83.4 million liability accrual, which is a significant concern for investors.

Guardant Health, Inc. (GH) filed an 8-K on February 22, 2024, primarily to report its financial results for the fiscal quarter and year ended December 31, 2023. The key information for investors is contained within the press release furnished as Exhibit 99.1. While the 8-K itself doesn't provide the detailed financial figures, it officially announces that these results are now public. Investors should refer to the furnished press release for specific revenue, earnings, and other operational metrics for the fourth quarter and full year 2023, as well as any forward-looking guidance provided by the company.

Guardant Health, Inc. (GH) announced a change in its Board of Directors through an 8-K filing on February 1, 2024. Specifically, Mr. Samir Kaul has notified the Board of his intention to resign as a director and as a member of the compensation committee, effective February 1, 2024. This departure is stated to be amicable, with no disputes or disagreements cited as the reason for his resignation. Following Mr. Kaul's resignation, the size of the Board will be reduced from nine to eight directors. Investors should note that while this filing details a director's departure, it does not appear to be related to any operational or policy disagreements, suggesting a smooth transition. The reduction in board size is a minor structural adjustment and is not expected to have a significant immediate impact on the company's strategic direction or operational performance.

Guardant Health, Inc. (GH) filed an 8-K on January 8, 2024, to announce preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2023. While the filing itself does not contain the specific financial figures, it states that a press release with this information has been furnished as an exhibit. Investors should refer to Exhibit 99.1 for the detailed preliminary financial results, which will be crucial for assessing the company's recent performance and future outlook. Additionally, the company indicated that a presentation for the 2024 J.P. Morgan Healthcare Conference, also scheduled for January 8, 2024, would be made available on their investor website. This presentation may offer further insights into the company's strategy, operational updates, and financial projections. It's important to note that the information furnished in this report is not considered 'filed' for regulatory purposes, meaning it doesn't carry the same liability implications as formally filed financial statements.

Guardant Health, Inc. (GH) announced on December 21, 2023, the successful completion of a registered direct offering, raising approximately $90.7 million in gross proceeds. The company sold 3,387,446 shares of common stock to certain institutional investors at an offering price of $26.77 per share. This offering was conducted under the company's existing shelf registration statement, ensuring an efficient capital raise. The net proceeds, estimated at $90.6 million after expenses, are earmarked for general corporate purposes. This includes crucial areas such as working capital, operating expenses, and capital expenditures, which will support the company's ongoing operations and strategic initiatives. The offering's closing occurred on December 21, 2023, following the execution of a common stock purchase agreement on December 20, 2023.

Guardant Health, Inc. (GH) has announced a significant milestone in the regulatory process for its Shield blood test, a diagnostic for colorectal cancer screening. The U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee has tentatively scheduled a review of the Premarket Approval (PMA) application for the Shield test for March 28, 2024. This is a critical step towards potential FDA approval and commercialization, offering investors insight into the timeline for this important product. While the date is tentative and subject to confirmation, this scheduling indicates progress and a clear path forward for the Shield test review. Investors will be closely watching this upcoming advisory committee meeting, as a positive outcome could pave the way for broader adoption of Guardant Health's non-invasive screening technology, potentially impacting future revenue streams and market position in the oncology diagnostics space.

Guardant Health, Inc. (GH) has filed an 8-K report detailing a significant development in a patent infringement lawsuit. On November 14, 2023, a jury in the U.S. District Court for the District of Delaware found Guardant Health to have willfully infringed upon two patents owned by TwinStrand Biosciences, Inc. and the University of Washington. The jury awarded the plaintiffs $83.4 million in damages, calculated as a 6% royalty on past sales. The company strongly disagrees with the verdict and intends to pursue post-trial motions to overturn it, seek a new trial, or amend the judgment. Guardant Health also plans to appeal any adverse rulings to the U.S. Court of Appeals for the Federal Circuit. While Guardant Health states it does not expect the verdict to materially impact its current business operations, it acknowledges a potential impact on future expenses if royalty payments are mandated on future sales, especially given the jury's finding of willful infringement which could lead to enhanced damages.

Guardant Health, Inc. (GH) filed an 8-K on November 6, 2023, to report its financial results for the fiscal quarter ended September 30, 2023. The key information is contained within the accompanying press release, which details the company's performance and financial condition. Investors should note that this information is furnished and not deemed "filed" for certain regulatory purposes, though it is incorporated by reference into the 8-K. While the specific financial figures are not detailed within the 8-K text itself, the filing serves as the official channel for announcing these results. Investors relying on this report should access the furnished press release (Exhibit 99.1) for the actual revenue, earnings per share, and any updated guidance or strategic commentary provided by the company. This allows for a timely assessment of Guardant Health's recent operational success and its trajectory.

Guardant Health, Inc. (GH) reported strong revenue growth in its third-quarter and year-to-date filings for 2023, driven primarily by its Precision Oncology Testing segment. Total revenue increased by 22% year-over-year for the quarter to $143 million and by 27% year-to-date to $408.9 million. This growth was supported by increased test volumes in both clinical and biopharmaceutical customer segments. Despite revenue expansion, the company continued to incur significant net losses, with a Q3 net loss of $86.1 million and a year-to-date net loss of $292.4 million. However, the net loss narrowed considerably compared to the previous year, particularly for the nine-month period, indicating improved operational efficiency or cost management. The company strengthened its financial position, ending the period with $457.3 million in cash and cash equivalents and $697.5 million in short-term marketable debt securities, totaling over $1.15 billion in liquid assets. This robust liquidity is bolstered by a $381.4 million net proceeds from a follow-on public offering completed in May 2023, providing significant runway for continued investment in R&D and commercial expansion. Key developments include continued progress on the Shield test for early cancer detection, with an FDA PMA submission and positive results from the ECLIPSE study, positioning the company for potential future growth in the early detection market.

Guardant Health, Inc. (GH) announced the resignation of its Chief Operating Officer, Ms. Ines Dahne-Steuber, effective November 10, 2023. While she will be departing from her COO role, Ms. Dahne-Steuber will continue to be employed by the company until December 1, 2023, to ensure a smooth transition of her responsibilities. This development marks a significant change in the company's executive leadership team, and investors will be keen to understand the reasons behind the departure and the plan for succession. The company has not yet announced a replacement for the COO position. The transition period through December 1st suggests an orderly handover is being prioritized. Investors should monitor future filings and announcements for updates on the new COO appointment and any strategic implications this change may have on Guardant Health's operations and growth trajectory.

Guardant Health, Inc. announced its upcoming Investor Day event scheduled for September 7, 2023. This event will feature presentations from co-CEOs Helmy Eltoukhy and AmirAli Talasaz, along with other executive management members. The primary focus will be on providing updates regarding the company's operations, key strategic priorities, and its financial outlook. Investors are encouraged to attend or access the live and archived webcast of the presentation through the "Investors" section of Guardant Health's website. This disclosure is made under Regulation FD, and while it provides important forward-looking information, it is furnished and not deemed "filed" under the Securities Exchange Act of 1934, meaning it does not carry the same liability as formally filed documents.